Horizon 2020 SME
Dec 2017
FABPulous founder Jan Glatz Nominated for European Inventor 2018

MAASTRICHT, Oct 16, 2017 – The EASME at the European Commission nominated FABPulous BV’s founder Jan Glatz and Ger Biesbrouck of Medavinci Development, Amsterdam on Monday for the prestigious European Inventor Award 2018 in the SME category for their work in the development of the H-FABP True Rapid Test®.

Glatz, who is Professor of Cardiac Metabolism at the Cardiovascular Research Institute Maastricht (CARIM) at Maastricht University was nominated for the development of a rapid Plasma Separation Device and Integrated Assay concept which enables healthcare workers to determine whether chest pain patients are having a heart attack within five minutes. Biesbrouck, CEO of Medavinci Development, helped in the design of the plasma separation device that provides a correctly diluted plasma sample from finger prick blood in just a few seconds

The H-FABP True Rapid Test®, a blood filtration device, is capable of providing swift and reliable detection of a small protein found in capillary blood after a heart attack.

“It’s an honour to be nominated for work that is focused on solving one of the thorniest problems for emergency medicine practitioners, healthcare systems and cardiac patients,” Glatz said.

Up to 5 million people suffering from chest pains are assessed by healthcare staff in medical facilities across the European Union every year. About 20% of those cases will be associated with a life-threatening heart attack.

The remaining 80% will be diagnosed with something less urgent and sent home after an extensive wait. More than 2 million will be admitted to hospitals overnight at a cost of €4 billion each year.

The results are overcrowded hospital emergency departments, fewer available hospital beds and excessive healthcare costs because current diagnostic standards, including laboratory-based tests for the biomarker Troponin, don’t provide the certainty needed to discharge patients any earlier.

The H-FABP True Rapid Test® can reliably detect chest pain patients who are at imminent risk of a heart attack in five minutes by measuring the amount of Heart-Fatty Acid Binding Protein (H-FABP) in the patient’s blood. Doctors can then send patients at risk directly to cardiology and send home those not at risk. That saves lives, clears emergency and hospital beds and saves money.

The European Inventor Award, now in its 12th year, is one of Europe’s most prestigious innovation prizes. Launched by the European Patent Office (EPO) in 2006, the annual award distinguishes inventors whose pioneering work provide answers to some of the biggest challenges of our times.

 

For further information please contact:

Conor O’Brien, Chief Executive Officer – email at c.obrien@fabpulous.com

 

FABPulous BV 
Marconistraat 16
3029 AK Rotterdam
Netherlands

FABPulous Ltd
St John’s Innovation Centre
Cowley Road, Cambridge
CB4 0WS, UK